Anti-HLA-DR Antibody (9L140) is a Rabbit antibody targeting HLA-DR. Anti-HLA-DR Antibody (9L140) can be used in WB,IHC-P,IHC-Fr,IF.

IgG

9L140

Human

WB: 1:1000-5000; IHC-P: 1:1000-5000; IHC-Fr: 1:1000-5000; IF: 1:500-2000

Monoclonal

A synthesized peptide: human HLA DRA

Human

HLA-DRA

HLA class II histocompatibility antigen, DR alpha chain

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments.